IP Verse

Rapid Dissolution Formulation Of A Cinacalcet Hcl

PatentPatent Analysis

EP3395339

AMGEN
Application Number
EP18175497A
Filing Date
Sep 10, 2004
Status
Revoked
Oct 14, 2022
Grant Date
Dec 11, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3570885B1
EP4209499B1
EP3819007B1

Biblio Summary

The patent EP3395339B8 was granted to Amgen on Dec 11, 2019 following the initial filing on Sep 10, 2004 under the application number EP18175497A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALDec 23, 2020INTERVENTION ADMISSIBLE
BETAPHARM ARZNEIMITTELDec 9, 2020INTERVENTION ADMISSIBLE
AECHTERJan 17, 2020ADMISSIBLE
BIOGARANJan 17, 2020ADMISSIBLE
MAIWALDJan 17, 2020ADMISSIBLE
ZENTIVAJan 17, 2020ADMISSIBLE
ACCORD HEALTHCAREJan 17, 2020WITHDRAWN
GILLARDJan 16, 2020ADMISSIBLE
GLENMARK PHARMACEUTICALS EUROPEJan 16, 2020ADMISSIBLE
HGFJan 16, 2020ADMISSIBLE
TEVA PHARMACEUTICALSJan 13, 2020WITHDRAWN

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents